Equillium (EQ) Expected to Release Earnings on Thursday

Equillium (NASDAQ:EQ) is expected to issue its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($0.05) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:00 PM ET.

Equillium (NASDAQ:EQ) last posted its earnings results on Thursday, August 13th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. On average, analysts expect Equillium to post ($0.21) EPS for the current fiscal year and ($0.24) EPS for the next fiscal year.

Equillium Stock Performance

Equillium stock opened at $1.40 on Thursday. The company has a market capitalization of $88.77 million, a P/E ratio of -7.00 and a beta of 2.08. Equillium has a fifty-two week low of $0.76 and a fifty-two week high of $3.54. The stock has a 50-day simple moving average of $1.72 and a 200-day simple moving average of $2.07.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on EQ. Wall Street Zen cut Equillium from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Roth Capital restated a “buy” rating on shares of Equillium in a research report on Monday, October 26th. Leerink Partners assumed coverage on shares of Equillium in a report on Monday, October 12th. They issued an “outperform” rating and a $6.00 target price on the stock. Zacks Research upgraded shares of Equillium from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Finally, Piper Sandler began coverage on shares of Equillium in a report on Monday, July 13th. They issued an “overweight” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.57.

Equillium Company Profile

Equillium, Inc is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company seeks to address immune-system dysregulation by developing treatments that selectively modulate immune-cell activity rather than broadly suppressing the immune system.

Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, a protein involved in the activation and trafficking of certain T cells. The company has evaluated itolizumab in conditions including acute graft-versus-host disease and lupus nephritis.